e-learning
resources
European Respiratory Review
2006
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Tiotropium as essential maintenance therapy in COPD
Decramer M.
Source:
Eur Respir Rev 2006; 15: 51-57
Journal Issue:
December 2006 - 15 (99)
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Decramer M.. Tiotropium as essential maintenance therapy in COPD. Eur Respir Rev 2006; 15: 51-57
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 19: 217-224
Year: 2002
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium
Source: Eur Respir J 2002; 19: 209-216
Year: 2002
Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD
Source: Eur Respir J 2004; 23: 832-840
Year: 2004
Resistance to resistance
Source: Annual Congress 2007 - Primary care: delivering the goods: "inhaled therapies"
Year: 2007
Roflumilast with long-acting ?2-agonists for COPD: influence of exacerbation history
Source: Eur Respir J 2011; 38: 553-560
Year: 2011
Bronchodilator responsiveness in patients with COPD
Source: Eur Respir J 2008; 31: 742-750
Year: 2008
Exercise and dyspnoea in COPD
Source: Eur Respir Rev 2006; 15: 72-79
Year: 2006
Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT(R) trial
Source: Eur Respir J 2010; 36: 65-73
Year: 2010
Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 19: 639-644
Year: 2002
Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance
Source: Eur Respir Rev 2006; 15: 37-41
Year: 2006
Long-term efficacy of repeated pulmonary rehabilitation programs (PRP) in chronic airway obstruction (CAO)
Source: Annual Congress 2005 - Pulmonary rehabilitation: an evidence-based intervention
Year: 2005
The role of bronchodilator treatment in the prevention of exacerbations of COPD
Source: Eur Respir J 2012; 40: 1545-1554
Year: 2012
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 74-81
Year: 2003
Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility
Source: Eur Respir J 2002; 20: Suppl. 38, 243s
Year: 2002
Seasonal variations in exercise tolerance, activity and quality of life in patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2005 - Pulmonary rehabilitation: an evidence-based intervention
Year: 2005
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease
Source: Eur Respir J 2004; 23: 241-249
Year: 2004
Exacerbation and hospitalization in COPD patients with long-term high-intensity NPPV
Source: Annual Congress 2007 - Technological progress in noninvasive ventilation
Year: 2007
Tiotropium + olodaterol in patients with moderate to severe COPD with chronic bronchitis and/or emphysema
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept